SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531 · Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
PhasePhase 2
TypeInterventional
Age5 Years – 40 Years
WhereSan Francisco, California, United States + 70 more
SponsorSAb Biotherapeutics, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts
71 sitesApply